Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?
Identifieur interne : 001790 ( Main/Exploration ); précédent : 001789; suivant : 001791Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?
Auteurs : Shahir S. Hamdulay [Royaume-Uni] ; Justin C. Mason [Royaume-Uni]Source :
- Heart [ 1355-6037 ] ; 2009-09-15.
English descriptors
- Teeft :
- Anakinra, Arthritis, Atherosclerosis, Biological therapies, British society, Bywaters center, Cardiovascular, Cardiovascular disease, Cardiovascular sciences, Disease activity, Dysfunction, Endothelial, Endothelial dysfunction, Erythematosus, Etanercept, Hammersmith hospital, Inflammation, Inflammatory, Infliximab therapy, Insulin resistance, Lupus, Methotrexate, Myocardial deformation, Myocardial infarction, Necrosis factor, Pathogenesis, Prednisolone, Receptor, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatology biologics, Subclinical atherosclerosis, Systemic inflammation, Systemic lupus erythematosus, Tnfa, Tnfa antagonists, Traditional risk factors, Vascular inflammation, Ventricular function.
Url:
DOI: 10.1136/hrt.2009.171561
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001F97
- to stream Istex, to step Curation: 001F97
- to stream Istex, to step Checkpoint: 000715
- to stream Main, to step Merge: 001794
- to stream Main, to step Curation: 001790
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?</title><author><name sortKey="Hamdulay, Shahir S" sort="Hamdulay, Shahir S" uniqKey="Hamdulay S" first="Shahir S" last="Hamdulay">Shahir S. Hamdulay</name></author><author><name sortKey="Mason, Justin C" sort="Mason, Justin C" uniqKey="Mason J" first="Justin C" last="Mason">Justin C. Mason</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:69F7398266FCBD10974FB04C732BDAC6F741AEAC</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1136/hrt.2009.171561</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-309MPN3H-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001F97</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F97</idno><idno type="wicri:Area/Istex/Curation">001F97</idno><idno type="wicri:Area/Istex/Checkpoint">000715</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000715</idno><idno type="wicri:doubleKey">1355-6037:2009:Hamdulay S:disease:modifying:anti</idno><idno type="wicri:Area/Main/Merge">001794</idno><idno type="wicri:Area/Main/Curation">001790</idno><idno type="wicri:Area/Main/Exploration">001790</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?</title><author><name sortKey="Hamdulay, Shahir S" sort="Hamdulay, Shahir S" uniqKey="Hamdulay S" first="Shahir S" last="Hamdulay">Shahir S. Hamdulay</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cardiovascular Sciences, Bywaters Center for Vascular Inflammation, National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Mason, Justin C" sort="Mason, Justin C" uniqKey="Mason J" first="Justin C" last="Mason">Justin C. Mason</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cardiovascular Sciences, Bywaters Center for Vascular Inflammation, National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Heart</title><title level="j" type="abbrev">Heart</title><idno type="ISSN">1355-6037</idno><idno type="eISSN">1468-201X</idno><imprint><publisher>BMJ Publishing Group Ltd and British Cardiovascular Society</publisher><date type="published" when="2009-09-15">2009-09-15</date><biblScope unit="volume">95</biblScope><biblScope unit="issue">18</biblScope><biblScope unit="page" from="1471">1471</biblScope></imprint><idno type="ISSN">1355-6037</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1355-6037</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Anakinra</term><term>Arthritis</term><term>Atherosclerosis</term><term>Biological therapies</term><term>British society</term><term>Bywaters center</term><term>Cardiovascular</term><term>Cardiovascular disease</term><term>Cardiovascular sciences</term><term>Disease activity</term><term>Dysfunction</term><term>Endothelial</term><term>Endothelial dysfunction</term><term>Erythematosus</term><term>Etanercept</term><term>Hammersmith hospital</term><term>Inflammation</term><term>Inflammatory</term><term>Infliximab therapy</term><term>Insulin resistance</term><term>Lupus</term><term>Methotrexate</term><term>Myocardial deformation</term><term>Myocardial infarction</term><term>Necrosis factor</term><term>Pathogenesis</term><term>Prednisolone</term><term>Receptor</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatology biologics</term><term>Subclinical atherosclerosis</term><term>Systemic inflammation</term><term>Systemic lupus erythematosus</term><term>Tnfa</term><term>Tnfa antagonists</term><term>Traditional risk factors</term><term>Vascular inflammation</term><term>Ventricular function</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hamdulay, Shahir S" sort="Hamdulay, Shahir S" uniqKey="Hamdulay S" first="Shahir S" last="Hamdulay">Shahir S. Hamdulay</name></region><name sortKey="Mason, Justin C" sort="Mason, Justin C" uniqKey="Mason J" first="Justin C" last="Mason">Justin C. Mason</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001790 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001790 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:69F7398266FCBD10974FB04C732BDAC6F741AEAC
|texte= Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?
}}
| This area was generated with Dilib version V0.6.33. |  |